Dr. Howard Verrico reports

SIRONA BIOCHEM SIGNS AGREEMENT WITH GLOBAL PHARMACEUTICAL COMPANY FOR CLINICAL TRIAL OF ITS NOVEL SKINCARE COMPOUND TFC-1067

Sirona Biochem Corp. has signed an agreement with a top 10 global pharmaceutical company to jointly test Sirona's novel skin care, dark spot remover, TFC-1067, in a new clinical study. TFC-1067 will be tested using a new higher concentration (0.4 per cent) and advanced formulation.

The clinical trial, launched Oct. 5, will run for a period of 12 weeks and include a minimum of 125 participants. It will be managed by Dermscan (a division of Eurofins), a global leader in cosmetic clinical trials. The study's end point is to determine the compound's ability to reduce hyperpigmentation or dark spots of the skin.

Multiple parameters will be measured including the added effects of the higher concentration of TFC-1067 and a boosted formulation. The study is expected to complete in early 2021 with results in February, 2021. The study protocol was established through a collaboration of the scientific teams of TFChem, Sirona's wholly owned subsidiary and the company's skin care scientific team.

Following the study, the company will have first access to the clinical study results to assess potential use by its subsidiary dermatology company.

"To have a partner of this magnitude assisting in the design and financing of our clinical trial is a testament to the potential of TFC-1067," said Dr. Howard Verrico, chief executive officer of Sirona Biochem. "We look forward to continuing our relationship with their clinical team through the study as we evaluate the higher dose and improved formulation of the compound. TFC-1067 has been clinically proven to selectively lighten dark spots and blend them into surrounding skin tone. The ability to lessen visibility of dark spots while preserving underlying skin tone safely is a unique consumer benefit."

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

We seek Safe Harbor.